Milton Wong, MD
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1942200498
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,200 of the $7,068 with a category attached, or 73.6%. AbbVie accounts for 79.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $3,447 and has fallen 84.3% since, to $541 in 2025.
Across 65 payments — averaging $108.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Ascendis Pharma Endocrinology Inc$299
- AstraZeneca$201
- Novo Nordisk$179
- Bayer$125
- Abbott$120
- plus $552 from 20 others
Across 2 payments — averaging $2849.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$5K
- Sanofi US Services Inc.$635
What the payments were for
- Speaking & faculty fees$5,20074%
- Food & beverage$1,80125%
- Education$80%
- Gifts$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $5,591 |
| Ascendis Pharma Endocrinology Inc | 5 | $299 |
| AstraZeneca | 5 | $201 |
| Novo Nordisk | 5 | $179 |
| Bayer | 1 | $125 |
| Abbott | 8 | $120 |
| Mannkind Corporation | 4 | $103 |
| Boehringer Ingelheim | 4 | $67 |
| Medtronic | 2 | $39 |
| Insulet Corporation | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| IBSA Pharma Inc. | 2 | $29 |
| Merck | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Amgen | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,068 in reported general payments places this provider in the 60th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $239,816 |
| RybelsusSemaglutide | 74 | $152,839 |
| MounjaroTirzepatide | 85 | $130,387 |
| FarxigaDapagliflozin Propanediol | 77 | $101,218 |
| JardianceEmpagliflozin | 71 | $88,905 |
| TrulicityDulaglutide | 17 | $22,618 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $21,603 |
| SynthroidLevothyroxine Sodium | 210 | $19,251 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $18,756 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $17,122 |
| Humalog Kwikpen U-100Insulin Lispro | 33 | $10,267 |
| Novolog FlexpenInsulin Aspart | 26 | $10,212 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $9,412 |
| TirosintLevothyroxine Sodium | 16 | $5,959 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 46 | $5,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $179 | $392,654211 claims |
| Lilly USA, LLCMounjaro, Trulicity | $16 | $153,005102 claims |
| AstraZenecaFarxiga | $201 | $101,21877 claims |
| Boehringer IngelheimJardiance | $67 | $88,90571 claims |
| AbbVieSynthroid, Armour Thyroid | $5,591 | $20,229223 claims |
| IBSA Pharma Inc.Tirosint | $29 | $5,95916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$466K
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Serena KlughLas Vegas$14K
- Betsy PalalLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.